LiveNews Provides news reports of information as it happens in real time of politics, business, the economy and also reports on global issues and events from a New Zealand viewpoint.
HKQAA International Symposium Sustainable Finance, ESG And Climate Resilience Hong Kong 2023 Successfully Held menafn.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from menafn.com Daily Mail and Mail on Sunday newspapers.
APL-106 (uproleselan) Granted Breakthrough Therapy Designation in China for the Treatment of Acute Myeloid Leukemia
Foster City, CA, Hangzhou, CH, Gaithersburg, MD, Jan 07, 2021 - (ACN Newswire) - Apollomics, Inc., an innovative biopharmaceutical company committed to the discovery and development of mono- and combination- oncology therapies, and GlycoMimetics (Nasdaq: GLYC), today announced APL-106 (uproleselan) has been granted Breakthrough Therapy Designation (BTD) from the China National Medical Products Administration (NMPA) Center for Drug Evaluation (CDE) for the treatment of relapsed/refractory acute myeloid leukemia (AML). This Breakthrough Therapy Designation for APL-106 reinforces its potential and is an important regulatory milestone for Apollomics as we prepare to initiate our clinical development work in China for patients suffering from AML, said Guo-Liang Yu, PhD, Co-Founder, Chairman and Chief Executive Officer. AML is an aggressive disease and relapsed/refracto